Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Communiqué de presse : Opella : étape clé franchie pour l’étude consacrée au Cialis Opella : étape clé franchie pour l’étude consacrée au Cialis Paris, le 21 janvier 2025. Opella, l’activité Santé...
Press Release: Opella reaches study milestone for Cialis Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US...
Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...
Sanofi: Information concerning the total number of voting rights and shares – November 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Approval based on positive pivotal ICARIA-MM phase 3 study using the...
Communiqué de presse : La nouvelle formulation sous-cutanée du Sarclisa a satisfait aux co-critères d’évaluation primaires de l’étude de phase III IRAKLIA dans le myélome multiple La nouvelle...
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary...
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma New Sarclisa subcutaneous formulation met co-primary endpoints in the...
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.74 | 3.92527287993 | 95.28 | 100.12 | 93.06 | 1823985 | 96.90483083 | DE |
| 4 | 6.1 | 6.56478691347 | 92.92 | 100.12 | 91.75 | 1319603 | 95.54316318 | DE |
| 12 | -2.08 | -2.05736894164 | 101.1 | 101.9 | 87.5 | 1556636 | 93.57151419 | DE |
| 26 | 5.82 | 6.24463519313 | 93.2 | 106.14 | 87.5 | 1494030 | 97.19743119 | DE |
| 52 | 5.31 | 5.66641767154 | 93.71 | 106.14 | 84.93 | 1464557 | 93.40301174 | DE |
| 156 | 6.89 | 7.47856290025 | 92.13 | 106.66 | 76.45 | 1736641 | 92.81921852 | DE |
| 260 | 7.22 | 7.86492374728 | 91.8 | 106.66 | 67.65 | 1933409 | 89.44542746 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
